Combining standard adjuvant chemotherapy with the immune checkpoint inhibitor atezolizumab [Tecentriq] leads to a significant improvement in disease-free survival in a subset of patients with Stage ...

Results from the Phase III SERENA-6 clinical trial found that switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for ...

A pre-surgical combination therapy including pembrolizumab [Keytruda] plus dabrafenib [Tafinlar] and trametinib [Mekinist] (DTP) significantly improved survival in patients with rare BRAF ...

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, ...

People who used GLP-1 receptor agonists, like Ozempic, had a modestly lower risk for obesity-related malignancies, especially colon and rectal cancer.

Welcoming participants to the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place this week Chicago, ASCO CEO Clifford Hudis, MD, acknowledged the detrimental effects of ...

Living with cancer can have detrimental effects on bone health, leading to pain, impaired mobility and increased risk of fractures. But there are ways to prevent and manage bone problems to help ...